Education
About Us
Working with TipRanks
Follow Us
Traws Pharma (TRAW)
NASDAQ:TRAW
TRAW Stock Chart & Stats
$1.68
-$0.87(-9.63%)
At close: 4:00 PM EST
$1.68
-$0.87(-9.63%)
Day’s Range― - ―
52-Week Range$0.97 - $3.27
Previous CloseN/A
Volume35.69K
Average Volume (3M)206.36K
Market Cap
$13.42M
Enterprise Value-$5.07M
Total Cash (Recent Filing)$13.08M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.46
Next Earnings
Mar 12, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding7,990,867
10 Day Avg. Volume403,079
30 Day Avg. Volume206,356
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.44
Price to Sales (P/S)61.01
P/FCF Ratio-0.46
Enterprise Value/Market Cap-0.38
Enterprise Value/Revenue-1.82
Enterprise Value/Gross Profit-1.82
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$7.25Price Target Upside331.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Clinical ProgressCompleting Phase 2 enrollment with favorable interim safety and efficacy signals materially raises the likelihood of clear next-step data readouts and regulatory discussions. Durable clinical momentum strengthens the company’s positioning versus ritonavir-based options and supports long-term commercial potential.
Regulatory Pathway And Strategic Stockpile RelevanceAn IND filing that positions a compound for BARDA consideration creates a structural commercial channel beyond retail sales. Inclusion in strategic stockpiles or government programs can produce stable, large-volume demand and de-risks revenue concentration for a clinical-stage antiviral developer over multiple years.
No Debt On Balance SheetA debt-free capital structure lowers fixed financial obligations and interest expense, preserving operational flexibility while advancing costly clinical programs. For a pre-commercial biotech, absence of leverage improves resilience to revenue variability and reduces bankruptcy/default tail risk.
Bears Say
Widening Losses And Accelerating Cash BurnRapidly increasing net losses and operating cash outflows materially shorten runway and raise near-term external funding needs. This structural cash consumption elevates dilution and execution risk, potentially forcing financing or program prioritization that could delay or curtail planned clinical milestones.
Negative Shareholders' EquityNegative equity reflects accumulated operating losses that weaken balance-sheet cushioning and limit borrowing capacity. This persistent deficit diminishes counterparty confidence and can complicate partnership, licensing, or supplier negotiations, increasing structural funding and operational fragility.
Minimal And Immaterial Revenue BaseWith negligible recurring revenue, the business remains fully dependent on R&D milestones and external capital. Lack of diversified commercial income means trial outcomes and financing cycles will determine sustainability, increasing long-term execution risk absent successful product approvals or durable partnerships.
Traws Pharma News
TRAW FAQ
What was Traws Pharma’s price range in the past 12 months?
Traws Pharma lowest stock price was $0.97 and its highest was $3.27 in the past 12 months.
What is Traws Pharma’s market cap?
Traws Pharma’s market cap is $13.42M.
When is Traws Pharma’s upcoming earnings report date?
Traws Pharma’s upcoming earnings report date is Mar 12, 2026 which is in 7 days.
How were Traws Pharma’s earnings last quarter?
Traws Pharma released its earnings results on Nov 13, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.34.
Is Traws Pharma overvalued?
According to Wall Street analysts Traws Pharma’s price is currently Undervalued.
Does Traws Pharma pay dividends?
Traws Pharma does not currently pay dividends.
What is Traws Pharma’s EPS estimate?
Traws Pharma’s EPS estimate is -1.22.
How many shares outstanding does Traws Pharma have?
Traws Pharma has 7,990,867 shares outstanding.
What happened to Traws Pharma’s price movement after its last earnings report?
Traws Pharma reported an EPS of -$0.34 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -17.29%.
Which hedge fund is a major shareholder of Traws Pharma?
Currently, no hedge funds are holding shares in TRAW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Traws Pharma
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
TRAW Stock 12 Month Forecast
Average Price Target
$7.25
▲(331.55% Upside)
Technical Analysis
Ownership Overview
8.55% Insiders
1.15% Mutual Funds
27.58% Other Institutional Investors
62.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---